Sylvester Comprehensive Cancer Center

Running trials

• Recruiting

  Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)

  NCT07936266· Phase 1· Sunil G. Iyer· Source

• Recruiting

  Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

  NCT07278362· Phase 4· University of Miami· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

  NCT07469891· Phase 1· Prelude Therapeutics Incorporated· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  NCT07007559· Phase 2· ALX Oncology Inc.· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

  NCT07103018· Phase 1· K36 Therapeutics, Inc.· Source

• Recruiting

  A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07023627· Phase 2· Incyte Corporation· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

  NCT06975865· Phase 3· Sanofi· Source

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Nuvalent Inc.· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

  NCT06966453· Phase 1/2· Pfizer· Source

• Recruiting

  First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

  NCT06797999· Phase 1/2· Adcendo ApS· Source

• Recruiting

  Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  NCT06787612· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  NCT06876662· Phase 4· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  NCT06876649· Phase 4· Eli Lilly and Company· Source

• Recruiting

  STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

  NCT06975293· Phase 1/2· STORM Therapeutics LTD· Source

• Active, not recruiting

  Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

  NCT06736418· Phase 1· Abdera Therapeutics Inc.· Source

• Recruiting

  A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  NCT06778863· Phase 1· Clasp Therapeutics, Inc.· Source

• Recruiting

  Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

  NCT05745285· University of Miami· Source

• Recruiting

  Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

  NCT06660355· Phase 2· H. Lee Moffitt Cancer Center and Research Institute· Source

• Recruiting

  A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  NCT06581406· Phase 2/3· Replimune, Inc.· Source

• Active, not recruiting

  Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT06625320· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  NCT06561048· Phase 3· Corvus Pharmaceuticals, Inc.· Source

• Recruiting

  Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

  NCT06463665· Phase 2· Genelux Corporation· Source

• Recruiting

  Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

  NCT06553872· Phase 2· H. Lee Moffitt Cancer Center and Research Institute· Source

• Active, not recruiting

  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

  NCT06413498· Phase 3· Kite, A Gilead Company· Source

• Active, not recruiting

  SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

  NCT06208748· Phase 2· Sarcoma Alliance for Research through Collaboration· Source

• Active, not recruiting

  A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

  NCT06384261· Phase 2· OncoVerity, Inc.· Source

• Recruiting

  A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

  NCT06501196· Phase 1· BlossomHill Therapeutics· Source

• Active, not recruiting

  Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06223516· Phase 1· AbbVie· Source

• Active, not recruiting

  A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

  NCT05973487· Phase 1· TScan Therapeutics, Inc.· Source

• Recruiting

  A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

  NCT06158854· Phase 1/2· AbbVie· Source

• Active, not recruiting

  A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

  NCT06215118· Phase 1· Pfizer· Source

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Pfizer· Source

• Active, not recruiting

  Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

  NCT06225596· Phase 2· BicycleTx Limited· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

  NCT06003231· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

  NCT05987332· Phase 2/3· IDEAYA Biosciences· Source

• Recruiting

  Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

  NCT06057402· Phase 4· Pfizer· Source

• Recruiting

  A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

  NCT05797805· Phase 1/2· Iterion Therapeutics· Source

• Active, not recruiting

  A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

  NCT05929235· Phase 1· Flare Therapeutics Inc.· Source

• Recruiting

  Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  NCT05983432· Phase 1· SystImmune Inc.· Source

• Active, not recruiting

  A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

  NCT05812027· TScan Therapeutics, Inc.· Source

• Recruiting

  Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

  NCT05732831· Phase 1/2· Tango Therapeutics, Inc.· Source

• Active, not recruiting

  Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

  NCT05718869· Phase 2· City of Hope Medical Center· Source

• Active, not recruiting

  A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

  NCT05512390· Phase 1· AbbVie· Source

• Recruiting

  Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

  NCT05530421· Phase 2· University of Miami· Source

• Recruiting

  A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  NCT05592626· Phase 1/2· Marengo Therapeutics, Inc.· Source

• Active, not recruiting

  A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

  NCT05675449· Phase 1· Pfizer· Source

Showing 50 of 89.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma14 recruiting
• Lung cancer8 recruiting
• Childhood cancers7 recruiting
• Ovarian cancer6 recruiting
• Head and neck cancer5 recruiting
• Prostate cancer5 recruiting
• Colorectal cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Melanoma3 recruiting
• Myelodysplastic syndromes3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Sarcoma3 recruiting
• Triple-negative breast cancer3 recruiting
• Acute myeloid leukaemia2 recruiting
• Bladder cancer2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Endometrial cancer2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• Cervical cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Glioblastoma1 recruiting
• Kidney cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Pancreatic cancer1 recruiting
• Sickle cell disease1 recruiting
• Trigeminal neuralgia1 recruiting

Closed trials

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

  NCT05712694· Phase 3· Polaris Group· Source

• Terminated

  HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05553639· Phase 1/2· Hookipa Biotech GmbH· Source

• Terminated

  Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

  NCT05427812· Phase 1/2· Ichnos Sciences SA· Source

• Terminated

  A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

  NCT05070247· Phase 1/2· Takeda· Source

• Terminated

  Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

  NCT05359861· Phase 2· Coherus Oncology, Inc.· Source

• Terminated

  A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

  NCT05181540· Phase 3· Angiocrine Bioscience· Source

• Terminated

  MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

  NCT05090566· Phase 2· Pfizer· Source

• Terminated

  Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

  NCT04869943· Phase 3· Veru Inc.· Source

• Completed

  Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

  NCT05024045· Phase 1· Eli Lilly and Company· Source

• Completed

  A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

  NCT04526899· Phase 2· BioNTech SE· Source

• Terminated

  A Phase 1 Study of ADI-001 in B Cell Malignancies

  NCT04735471· Phase 1· Adicet Therapeutics· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Completed

  Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

  NCT04552223· Phase 2· Jose Lutzky, MD· Source

• Completed

  Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

  NCT04370704· Phase 1/2· Incyte Corporation· Source

• Terminated

  First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

  NCT04401020· Phase 1· Sanofi· Source

• Completed

  UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

  NCT04382664· Phase 2· Ultimovacs ASA· Source

• Completed

  TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

  NCT04306900· Phase 1· Trishula Therapeutics, Inc.· Source

• Completed

  IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

  NCT04109456· Phase 1· InxMed (Shanghai) Co., Ltd.· Source

• Terminated

  An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

  NCT04189614· Phase 1· AbbVie· Source

• Completed

  A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

  NCT04229004· Phase 3· Pancreatic Cancer Action Network· Source

• Terminated

  A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

  NCT04157517· Phase 1/2· Teva Branded Pharmaceutical Products R&D LLC· Source

• Completed

  A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

  NCT04180215· Phase 1/2· Hookipa Biotech GmbH· Source

• Completed

  A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

  NCT03740529· Phase 1/2· Loxo Oncology, Inc.· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors

  NCT03604783· Phase 1· Sumitomo Pharma America, Inc.· Source

• Completed

  Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

  NCT03675737· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

  NCT03534323· Phase 1/2· Dana-Farber Cancer Institute· Source

• Completed

  A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

  NCT03474107· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Completed

  1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

  NCT03133221· Phase 2· University of Maryland, Baltimore· Source

• Completed

  Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

  NCT03070392· Phase 2· Immunocore Ltd· Source

• Recruiting

  Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

  NCT03016819· Phase 3· Advenchen Laboratories, LLC· Source

• Completed

  A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

  NCT03143153· Phase 3· Bristol-Myers Squibb· Source

• Completed

  Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

  NCT03037385· Phase 1/2· Hoffmann-La Roche· Source

• Completed

  A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

  NCT02508467· Phase 1· Blueprint Medicines Corporation· Source

• Completed

  Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

  NCT02228681· Phase 2· GOG Foundation· Source

• Completed

  Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

  NCT01302834· Phase 3· Radiation Therapy Oncology Group· Source

• Completed

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  NCT00003641· Phase 3· ECOG-ACRIN Cancer Research Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer53 works · 7 trials
• Multiple myeloma50 works · 18 trials
• Melanoma39 works · 17 trials
• Myelodysplastic syndromes34 works · 4 trials
• Acute myeloid leukaemia30 works · 6 trials
• Sarcoma27 works · 12 trials
• Glioblastoma27 works · 3 trials
• Hodgkin lymphoma15 works · 2 trials
• Diffuse large B-cell lymphoma12 works · 3 trials
• Mantle cell lymphoma8 works · 4 trials
• Myeloproliferative neoplasms7 works · 4 trials
• Mesothelioma5 works · 2 trials
• Aplastic anaemia3 works · 0 trials